- Home
- INCY vs SBS Comparison
INCY vs SBS Comparison
Compare INCY & SBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- SBS
- Stock Information
- Founded
- INCY 1991
- SBS 1954
- Country
- INCY United States
- SBS Brazil
- Employees
- INCY N/A
- SBS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- SBS Water Supply
- Sector
- INCY Health Care
- SBS Utilities
- Exchange
- INCY Nasdaq
- SBS Nasdaq
- Market Cap
- INCY 17.0B
- SBS 14.4B
- IPO Year
- INCY 1993
- SBS 2002
- Fundamental
- Price
- INCY $108.14
- SBS $26.70
- Analyst Decision
- INCY Buy
- SBS
- Analyst Count
- INCY 19
- SBS 0
- Target Price
- INCY $89.19
- SBS N/A
- AVG Volume (30 Days)
- INCY 2.9M
- SBS 975.2K
- Earning Date
- INCY 10-28-2025
- SBS 11-10-2025
- Dividend Yield
- INCY N/A
- SBS 2.05%
- EPS Growth
- INCY 3878.02
- SBS N/A
- EPS
- INCY 5.90
- SBS 1.98
- Revenue
- INCY $4,813,105,000.00
- SBS $6,502,517,346.00
- Revenue This Year
- INCY $19.33
- SBS N/A
- Revenue Next Year
- INCY $10.47
- SBS $11.93
- P/E Ratio
- INCY $18.34
- SBS $13.42
- Revenue Growth
- INCY 18.09
- SBS N/A
- 52 Week Low
- INCY $53.56
- SBS $13.87
- 52 Week High
- INCY $109.28
- SBS $26.73
- Technical
- Relative Strength Index (RSI)
- INCY 83.44
- SBS 78.35
- Support Level
- INCY $91.16
- SBS $25.35
- Resistance Level
- INCY $108.81
- SBS $25.88
- Average True Range (ATR)
- INCY 4.51
- SBS 0.44
- MACD
- INCY 1.28
- SBS 0.17
- Stochastic Oscillator
- INCY 96.34
- SBS 98.97
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About SBS Companhia de saneamento Basico
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.